SCHEMBL4574585

SCHEMBL4574585

CCOC(=O)c1c(O)c(-c2cccs2)nn(CCC(C)(C)CC)c1=O

nearest known ligand 0.43

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 9/20 0.43
NPSR1 Q6W5P4 4/20 0.43
HPGD P15428 4/20 0.43
LMNA P02545 2/20 0.43
HTT P42858 2/20 0.43
ALDH1A1 P00352 9/20 0.42
HIF1A Q16665 1/20 0.41
MAPT P10636 2/20 0.41
GAA P10253 2/20 0.41
KEAP1 Q14145 1/20 0.41
TP53 P04637 1/20 0.41
POLB P06746 1/20 0.41
ADORA1 P30542 1/20 0.39
SMN1; SMN2 Q16637 2/20 0.39
TDP1 Q9NUW8 1/20 0.39
KMT2A Q03164 1/20 0.39
USP2 O75604 1/20 0.38
TSHR P16473 1/20 0.38
RECQL P46063 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4575054 0.92 KDM4E (0.45) KDM4ENPSR1HPGDLMNAHTT
SCHEMBL335086 0.84 ALDH1A1 (0.46) KDM4ENPSR1HPGDLMNAHTT
SCHEMBL14034290 0.83 ALDH1A1 (0.41) KDM4ENPSR1HPGDLMNAHTT
SCHEMBL14006532 0.79 ALDH1A1 (0.42) KDM4ENPSR1HPGDLMNAHTT
SCHEMBL14006667 0.79 TSHR (0.43) KDM4ENPSR1HPGDLMNAHTT
SCHEMBL5085613 0.79 FEN1 (0.44) KDM4ENPSR1HPGDLMNAHTT
SCHEMBL4908131 0.79 ALDH1A1 (0.40) KDM4ENPSR1HPGDLMNAHTT
SCHEMBL14038222 0.75 ADORA1 (0.44) KDM4ENPSR1HPGDLMNAHTT
SCHEMBL14034558 0.73 ADORA1 (0.45) KDM4ENPSR1HPGDLMNAHTT
SCHEMBL14007539 0.73 ADORA1 (0.44) KDM4ENPSR1HPGDLMNAHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080275032-A1 Pyridazinone compounds ANADYS PHARMACEUTICALS, INC. 2008-11-06 US disclosed
US-20080275032-A1 Pyridazinone compounds ANADYS PHARMACEUTICALS, INC. 2008-11-06 US disclosed
US-20080275032-A1 Pyridazinone compounds ANADYS PHARMACEUTICALS, INC. 2008-11-06 US disclosed
WO-2008082725-A1 PYRIDAZINONE COMPOUNDS ANADYS PHARMACEUTICALS, INC. (US) 2008-07-10 WO disclosed
WO-2008082725-A1 PYRIDAZINONE COMPOUNDS ANADYS PHARMACEUTICALS, INC. (US) 2008-07-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080275032-A1 Pyridazinone compounds HAVCR2, PLPBP, CYP3A43 KDM4E 3033/4885NPSR1 3482/4885HPGD 420/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.